Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
View/ Open
Date
2022-02-28ICR Author
Author
Kerrison, WGJ
Lee, ATJ
Thway, K
Jones, RL
Huang, PH
Type
Journal Article
Metadata
Show full item recordAbstract
Immunotherapy in soft tissue sarcoma (STS) has experienced a surge of interest in the past decade, contributing to an expanding number of therapeutic options for this extremely heterogenous group of rare malignancies. Immune checkpoint inhibitors (CPIs) targeting the PD-1 and CTLA-4 axes have demonstrated promising responses in a select number of STS subtypes, including rarer subtypes, such as alveolar soft part sarcoma, SWI/SNF-deficient sarcomas, clear cell sarcoma, and angiosarcoma. Multiple pan-subtype sarcoma trials have facilitated the study of possible predictive biomarkers of the CPI response. It has also become apparent that certain therapies, when combined with CPIs, can enhance response rates, although the specific mechanisms of this possible synergy remain unconfirmed in STS. In addition to CPIs, several other immune targeting agents, including anti-tumour-associated macrophage and antigen-directed therapies, are now under assessment in STS with promising efficacy in some subtypes. In this article, we review the state of the art in immunotherapy in STS, highlighting the pre-clinical and clinical data available for this promising therapeutic strategy.
Collections
Research team
Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology
Language
eng
Date accepted
2022-02-24
License start date
2022-02-28
Citation
Biomedicines, 2022, 10 (3), pp. 573 - ?
Publisher
MDPI